{"id":"https://openalex.org/W2903342525","doi":"https://doi.org/10.1080/14656566.2018.1552258","title":"Oral semaglutide for the treatment of type 2 diabetes","display_name":"Oral semaglutide for the treatment of type 2 diabetes","alternate_titles":[],"publication_year":2018,"publication_date":"2018-11-30","ids":{"openalex":"https://openalex.org/W2903342525","doi":"https://doi.org/10.1080/14656566.2018.1552258","mag":"2903342525","pmid":"https://pubmed.ncbi.nlm.nih.gov/30499733"},"language":"en","primary_location":{"id":"doi:10.1080/14656566.2018.1552258","doi":"https://doi.org/10.1080/14656566.2018.1552258","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14656566.2018.1552258","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2903342525"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030521441","display_name":"Maka S. Hedrington","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I126744593","display_name":"University of Maryland, Baltimore","ror":"https://ror.org/04rq5mt64","country_code":"US","type":"education","lineage":["https://openalex.org/I126744593"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maka S. Hedrington","raw_affiliation_strings":["Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA","institution_ids":["https://openalex.org/I126744593"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5080379883","display_name":"Stephen N. Davis","orcid":"https://orcid.org/0000-0001-8923-5209","observed_orcids":["https://orcid.org/0000-0001-8923-5209"]},"institutions":[{"id":"https://openalex.org/I126744593","display_name":"University of Maryland, Baltimore","ror":"https://ror.org/04rq5mt64","country_code":"US","type":"education","lineage":["https://openalex.org/I126744593"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Stephen N. Davis","raw_affiliation_strings":["Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA","institution_ids":["https://openalex.org/I126744593"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5080379883"],"corresponding_institution_ids":["https://openalex.org/I126744593"],"apc_list":null,"apc_paid":null,"fwci":5.1046,"has_fulltext":false,"cited_by_count":46,"citation_normalized_percentile":{"value":0.96621306,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"20","issue":"2","first_page":"133","last_page":"141"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oral-semaglutide","display_name":"oral semaglutide","score":0.9760000109672546},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9100000262260437},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9909999966621399},{"id":"https://openalex.org/keywords/absorption-enhancers","display_name":"absorption enhancers","score":0.9449999928474426},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.843999981880188},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.9459999799728394},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.875},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.8209999799728394},{"id":"https://openalex.org/keywords/cardiovascular-effects","display_name":"cardiovascular effects","score":0.47699999809265137},{"id":"https://openalex.org/keywords/antihyperglycemic-therapy","display_name":"antihyperglycemic therapy","score":0.7710000276565552}],"concepts":[{"id":"https://openalex.org/C2909862629","wikidata":"https://www.wikidata.org/wiki/Q27261089","display_name":"Semaglutide","level":5,"score":0.9408736228942871},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9372795820236206},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.7394270300865173},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.478098601102829},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.4399825632572174},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35211408138275146},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.17146208882331848},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.1439414620399475}],"mesh":[{"descriptor_ui":"D000068900","descriptor_name":"Sitagliptin Phosphate","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000069450","descriptor_name":"Liraglutide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000097789","descriptor_name":"Glucagon-Like Peptide-1 Receptor Agonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000099194","descriptor_name":"Semaglutide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001835","descriptor_name":"Body Weight","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1080/14656566.2018.1552258","doi":"https://doi.org/10.1080/14656566.2018.1552258","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14656566.2018.1552258","pdf_url":null,"source":{"id":"https://openalex.org/S52020611","display_name":"Expert Opinion on Pharmacotherapy","issn_l":"1465-6566","issn":["1465-6566","1744-7666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Pharmacotherapy","raw_type":"journal-article"},{"id":"pmid:30499733","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30499733","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on pharmacotherapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":17,"referenced_works":["https://openalex.org/W1965884363","https://openalex.org/W1993278282","https://openalex.org/W1998060558","https://openalex.org/W2007299070","https://openalex.org/W2058407858","https://openalex.org/W2111077824","https://openalex.org/W2111876001","https://openalex.org/W2152878394","https://openalex.org/W2160088494","https://openalex.org/W2607704626","https://openalex.org/W2766836053","https://openalex.org/W2795981708","https://openalex.org/W2800291410","https://openalex.org/W2808238332","https://openalex.org/W2808994737","https://openalex.org/W2809585820","https://openalex.org/W2894644761"],"related_works":["https://openalex.org/W3201282972","https://openalex.org/W3159005948","https://openalex.org/W4205769384","https://openalex.org/W3204790283","https://openalex.org/W4285589154","https://openalex.org/W2989987822","https://openalex.org/W3034070116","https://openalex.org/W3199150848","https://openalex.org/W3097603646","https://openalex.org/W4294191216"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Glucagon-like":[1],"peptide-1":[2],"(GLP-1)":[3],"receptor":[4,44],"agonists":[5],"are":[6,58],"highly":[7],"potent":[8],"antihyperglycemic":[9],"drugs":[10,145],"that":[11,146],"impose":[12],"low":[13],"risk":[14],"of":[15,28,55,75,82,110,119,139,142,170],"hypoglycemia":[16],"and":[17,52,60,93,100,105,108,129,158,168],"also":[18],"result":[19],"in":[20,46,89,96,114,127,173],"body":[21,94],"weight":[22,95],"reduction.":[23],"Currently,":[24],"all":[25],"approved":[26],"members":[27,118],"the":[29,56,73,120,137,166],"class":[30],"require":[31],"administration":[32],"by":[33],"injection.":[34],"Areas":[35],"covered:":[36],"This":[37],"manuscript":[38],"reviews":[39],"oral":[40,84,111,144,152,171],"semaglutide-an":[41],"experimental":[42],"GLP-1":[43],"agonist":[45],"phase-3":[47],"clinical":[48,53,79],"development.":[49],"Available":[50],"pharmacological":[51],"data":[54],"drug":[57],"reviewed,":[59],"important":[61],"end-points":[62],"described.":[63],"Expert":[64],"opinion:":[65],"Oral":[66],"peptide":[67],"delivery":[68],"has":[69,86],"become":[70],"possible":[71],"with":[72,98,116],"discovery":[74],"absorption":[76,131],"enhancers.":[77],"The":[78],"development":[80],"program":[81],"once-daily":[83],"semaglutide":[85,112,172],"shown":[87],"superiority":[88],"reducing":[90],"glycosylated":[91],"hemoglobin":[92],"comparison":[97],"placebo":[99],"active":[101],"comparators":[102],"(sitagliptin,":[103],"liraglutide,":[104],"empagliflozin).":[106],"Safety":[107],"tolerability":[109],"is":[113],"line":[115],"injectable":[117],"class.":[121],"Delayed":[122],"gastric":[123],"emptying,":[124],"local":[125],"increase":[126],"pH,":[128],"enhanced":[130],"do":[132],"not":[133],"seem":[134],"to":[135],"affect":[136],"exposure":[138],"a":[140],"number":[141],"other":[143],"have":[147],"been":[148],"tested":[149],"(metformin,":[150],"digoxin,":[151],"contraceptive":[153],"ethinylestradiol/levonorgestrel,":[154],"lisinopril,":[155],"warfarin,":[156],"furosemide":[157],"rosuvastatin).":[159],"Clinical":[160],"questions":[161],"for":[162],"further":[163],"investigation":[164],"include":[165],"effectiveness":[167],"safety":[169],"cardiovascular":[174],"indications.":[175]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2903342525","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":9}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2018-12-11T00:00:00"}
